Language

Pyclen CAS：78668-34-5

NAME:1,4,7,10-TETRAAZA-2,6-PYRIDINOPHANE CAS：78668-34-5 MF：C11H18N4 MW：206.29 COA:Provide Purity:95%+

Categories：

Material Chemistry

Other Material Chemicals

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

PRODUCT NAME	Pyclen
CAS NO	78668-34-5
Synonyms	3,6,9,15-Tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-triene; 1,4,7,10-Tetraaza-2,6-pyridinophane
BP	366.5±37.0 °C(Predicted)
DENSITY	1.000±0.06 g/cm3(Predicted)
STORAGE	2-8°C
DELIVERY	2-3DAYS
PACKAGE	According client's request

Description of Pyclen CAS：78668-34-5

3,6,9,15-Tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-triene is a ligand that binds to the nicotinic acetylcholine receptor (nAChR). It is an antagonist of nAChRs and blocks their activation by acetylcholine. 3,6,9,15-Tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-triene is used as a research tool to study the function of nAChRs in cell biology and pharmacology. The ligand has been shown to be an inhibitor of ion channels, such as potassium channels.

Applications of Pyclen CAS：78668-34-5

MRI and PET Applications
Pyclen has been used as a ligand for Manganese (II) in MRI and 52Mn PET applications . A new Pyclen-3,9-diacetate derivative ligand was synthesized to improve the dissociation kinetics of its Mn (II) complex . This ligand is less basic than the N-containing analogue due to the non-protonable O-atom

Radiopharmaceuticals for β-radiotherapy
Pyclen-dipicolinate chelates have been proven to be very efficient chelators for the radiolabeling with β –-emitters such as 90 Y . A pyclen-dipicolinate ligand functionalized with additional C12 alkyl chains was synthesized . The resulting 90 Y radiocomplex was observed to have a notable increase in lipophilicity .

Treatment of Liver or Brain Cancers
The lipophilic nature of the 90 Y radiocomplex allows it to be extracted in Lipiodol ® and encapsulated in biodegradable pegylated poly (malic acid) nanoparticles . This demonstrates the potential of lipophilic pyclen-dipicolinate derivatives as platforms for the design of radiopharmaceuticals for the treatment of liver or brain cancers by internal radiotherapy .

Nuclear Medicine
Pyclen-based radiopharmaceuticals have been used in nuclear medicine for the diagnosis and therapy of cancers . Due to the large range of radionuclides available and their different emitting properties, PET and SPECT imaging modalities can provide valuable information on the dysfunction or anomalies of organs in support of radiotherapy .

Targeted Dual-Photon Bioimaging
Pyclen-based lanthanide luminescent bioprobes have been synthesized and proven to be very suitable for two-photon microscopy . A strategy was developed to design bifunctional analogs of these bioprobes, providing additional reactive chemical groups for coupling with biological carriers, thereby achieving deep in vivo targeted two-photon bioimaging .

Research on New Ligands
Research is being conducted on new ligands of Pyclen. For example, a new Pyclen-3,9-diacetate derivative ligand was synthesized, possessing an etheric O-atom opposite to the pyridine ring, to improve the dissociation kinetics of its Mn (II) comple

Key words: